Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Preclinical evidence suggests that pharmacotherapy for obesity using combinations of agents targeted at distinct regulatory pathways may produce robust additive or synergistic effects on weight loss. This randomized placebo‐controlled trial examined the safety and efficacy of the amylin analogue pramlintide alone or in combination with either phentermine or sibutramine. All patients also received lifestyle intervention. Following a 1‐week placebo lead‐in, 244 obese or overweight, nondiabetic subjects (88% female; 41 ± 11 years; BMI 37.7 ± 5.4 kg/m 2; weight 103 ± 19 kg; mean ± s.d.) received placebo subcutaneously (sc) t.i.d., pramlintide sc (120 µg t.i.d.), pramlintide sc (120 µg t.i.d.) + oral sibutramine (10 mg q.a.m.), or pramlintide sc (120 µg t.i.d.) + oral phentermine (37.5 mg q.a.m.) for 24 weeks. Treatment was single‐blind for subjects receiving subcutaneous medication only and open‐label for subjects in the combination arms. Weight loss achieved at week 24 with either combination treatment was greater than with pramlintide alone or placebo (P < 0.001; 11.1 ± 1.1% with pramlintide + sibutramine, 11.3 ± 0.9% with pramlintide + phentermine, −3.7 ± 0.7% with pramlintide; −2.2 ± 0.7% with placebo; mean ± s.e.). Elevations from baseline in heart rate and diastolic blood pressure were demonstrated with both pramlintide + sibutramine (3.1 ± 1.2 beats/min, P < 0.05; 2.7 ± 0.9 mm Hg, P < 0.01) and pramlintide + phentermine (4.5 ± 1.3 beats/min, P < 0.01; 3.5 ± 1.2 mm Hg, P < 0.001) using 24‐h ambulatory monitoring. However, the majority of subjects receiving these treatments remained within normal blood pressure ranges. These results support the potential of pramlintide‐containing combination treatments for obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pickering, T. G., Hall, J. E., Appel, L. J., Falkner, B. E., Graves, J., Hill, M. N., Jones, D. W., Kurtz, T., Sheps, S. G., & Roccella, E. J. (2005) · Circulation · doi:10.1161/01.cir.0000154900.76284.f6 · Cited by 3,985
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503
Dixon, J. B., O’Brien, P. E., Playfair, J., Chapman, L., Schachter, L. M., Skinner, S., Proietto, J., Bailey, M., & Anderson, M. (2008) · JAMA · doi:10.1001/jama.299.3.316 · Cited by 1,434
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A. (2004) · Health Technology Assessment · doi:10.3310/hta8210 · Cited by 1,041
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
The gut and energy balance: visceral allies in the obesity wars
Badman, M. K., & Flier, J. S. (2005) · Science · doi:10.1126/science.1109951 · Cited by 532
Roth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436
Haddock, C., Poston, W., Dill, P., Foreyt, J., & Ericsson, M. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801889 · Cited by 303
Comparison of continuous and intermittent anorectic therapy in obesity.
Munro, J. F., MacCuish, A. C., Wilson, E. M., & Duncan, L. J. (1968) · BMJ · doi:10.1136/bmj.1.5588.352 · Cited by 215 · cited 1×
“4 kg has been reported in a 9-month study of phentermine not included in the meta-analysis (37).”
BackgroundAronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2003 · Cited by 178 · cited 1×
“Nausea, the most common adverse event in the pramlintidealone treatment group, was reported as a frequent adverse event in previous trials (12,29,31).”
BackgroundSelf-citation
Cited by
Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association
Bays, H. E., Toth, P. P., Kris-Etherton, P. M., Abate, N., Aronne, L. J., Brown, W. V., Gonzalez-Campoy, J. M., Jones, S. R., Kumar, R., La Forge, R., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.04.001 · Cited by 521
Self-citationAnti-obesity drugs: past, present and future
Rodgers, R. J., Tschöp, M. H., & Wilding, J. P. H. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.009621 · Cited by 430
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
“Long-acting amylin analogs continue to be investigated, alone or in combination with GLP-1R agonists, in clinical trials of subjects with obesity [19].”
BackgroundProgramming gene and engineered-cell therapies with synthetic biology
Kitada, T., DiAndreth, B., Teague, B., & Weiss, R. (2018) · Science · doi:10.1126/science.aad1067 · Cited by 281
Drug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195
Medical treatment of obesity: The past, the present and the future
Bray, G. A. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.015 · Cited by 109
Hendricks, E. J., Greenway, F. L., Westman, E. C., & Gupta, A. K. (2011) · Obesity · doi:10.1038/oby.2011.94 · Cited by 97
Update on obesity pharmacotherapy
Bray, G. A., & Ryan, D. H. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12328 · Cited by 88
Pharmacological management of binge eating disorder: current and emerging treatment options
McElroy, S., Guerdjikova, A. I., Mori, N., & O’Melia, A. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s25574 · Cited by 74
“Phentermine is currently under evaluation as a component in combination with topiramate and with pramlintide for weight loss in obesity.(63,112,113) There are no reports of phentermine monotherapy in BED, but two open-label trials evaluated the drug in combination with other treatments.”
Bays, H. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.125 · Cited by 66
Combination therapies for obesity
Camilleri, M., & Acosta, A. (2018) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0075 · Cited by 59
Leibel, R. L., Seeley, R. J., Darsow, T., Berg, E. G., Smith, S. R., & Ratner, R. (2015) · Diabetes · doi:10.2337/db15-0004 · Cited by 52
“Other combinations have been explored in humans, such as pramlintide/phentermine (108) and pramlintide/metreleptin (in subjects with BMI ,35 kg/m(2)) (109), however, development programs on these combinations have been discontinued due to commercial considerations.”
BackgroundJeon, E., Lee, K. Y., & Kim, K.-K. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23032 · Cited by 39
Treating the Chronic Disease of Obesity
Gossmann, M., Butsch, W. S., & Jastreboff, A. M. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.06.005 · Cited by 33
Amylin analogs for the treatment of obesity without diabetes: present and future
Panou, T., Gouveri, E., Popovic, D. S., & Papanas, N. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2409403 · Cited by 5
Metadata
- Authors
- Aronne, L. J., Halseth, A. E., Burns, C. M., Miller, S., & Shen, L. Z.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2010-09
- Volume
- 18
- Issue
- 9
- Pages
- 1739-1746
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2039778454
- Cited by
- 100
- References
- 11
- FWCI
- 9.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.